Sorin's Mitroflow valve comes of age – trial
This article was originally published in Clinica
Executive Summary
Cardiovascular giant Sorin has posted data showing its Mitroflow aortic pericardial heart valve still works 21 years after implantation. The information, which appears in the September issue of the Journal of Thoracic and Cardiovascular Surgery, is "the longest patient follow-up ever published in the history of pericardial valves", according to the Milan, Italy-based firm. It shows the biological valve, launched in Europe in 1982, to have "excellent durability" in addition to the "superior haemodynamic performance" Sorin already claims for the device.
You may also be interested in...
ITF Has A Fight On Its Hands In Duchenne
The group’s new muscular dystrophy pill seems unlikely to cut into Sarepta’s sales.
AbbVie Needs To Freshen Up
With half of its 2023 sales coming from aging blockbusters like Humira and Botox, AbbVie needs new blood.
AstraZeneca Pays $2bn To Keep Up With The Joneses
Bristol Myers Squibb and Lilly have recently done billion-dollar radiopharmaceuticals deals, and now the UK group wants a piece of the market. But can it make its Fusion fusion work?